Pfizer (Pfizer) is. See what "Pfizer" is in other dictionaries Pfizer pharmaceutical company
Her story begins in the distant 1849. At the beginning of the last century, the company entered the world level, but continued to develop, regularly offering consumers the latest medications. The article deals with the formation and development of Pfizer, as well as the Care of You project.
Founding of Pfizer
Today, Pfizer products are known all over the world. However, many years ago, when two enterprising young men - Pfizer and Ehart - decided to start their own business, they had neither money nor experience in such matters. However, the first had a degree in chemistry, and the second was a confectioner.
The father of one of the founders of the Pfizer brand helped with finances. Newly minted businessmen rented a small office in a very modest building located in one of the districts of New York, and began to master the pharmaceutical market.
Santonin
Pfizer's first drug was a drug based on santonin. It was used as an anthelmintic, but had many side effects. It was later superseded by safer drugs. Nevertheless, Pfizer gained instant popularity. The owners of the young company received the drug in the following way: santonin was mixed with almonds.
Lemon acid
In the eighties, the Pfizer company produced almost no drugs. She concentrated her energy on At this time, such drinks as Coca-Cola and Pepsi-Cola appeared. As you know, both the first and the second contain citric acid, the sale of which determined the growth of the company for many years.
Penicillin
At the beginning of the 20th century, the company established export-import relations. Most of the Pfizer preparations were made on the basis of citric acid. In 1928, A. Fleming conducted a study, as a result of which the antibiotic properties of penicillin mold were revealed.
This discovery was a huge contribution to pharmacology and medicine. Pfizer was now an expert in its field. Most of the antibiotic drugs shipped from the United States during World War II were manufactured under this brand name. In the thirties of the last century, production of B2 was also established. Antibiotic production started in 1967 a wide range- "Vibramycin", which later became the leader in sales.
Pfizer (90s)
In the last decade of the last century, the company launched the production and sale of the following products: Zoloft, Azithromycin, Norvask, Viagra. And again, Pfizer drugs are gaining popularity. The company receives the status of the most reliable and respected manufacturer in the world of pharmaceuticals.
"Zoloft" is a drug that normalizes the functioning of the nervous system. Sertraline is the main active element of this remedy, which is a strong antidepressant. They take Zoloft for panic attacks, social phobia and other nervous disorders. "Norvask" doctors prescribe for arterial hypertension, angina pectoris.
The invention of Viagra has become a real event in the world of medicine. As you know, this remedy is used in the treatment of erectile dysfunction. The company has invested more than three million dollars in the development of the drug.
In 1999, the manufacturer celebrated its 150th anniversary. Since the beginning of the new millennium, the Discovery Technology Center begins to function. In addition, as a result of the merger with Warner-Lambert, the company acquired the rights to manufacture and sell a number of medicines.
Pfizer: "Caring for You"
The list of drugs manufactured under the Pfizer trademark is regularly updated. Scientific research and development today is carried out under the guidance of world-class scientists. Pfizer products have been on the Russian market since 1992. Not so long ago, the Care for You program was launched, designed to increase the availability of medicines. The rules of participation are quite simple: you need to fill out a questionnaire in one of the pharmacies that are partners of the company and receive a discount card. With this card, you can later purchase Pfizer products.
Cardiac drugs are included in the list of medicines that Russian consumers have the opportunity to buy at a discount (10-50%). But in reality, this list is quite wide. It also includes drugs for the treatment of urological, ophthalmic pathologies, as well as diseases of the nervous system.
To participate in the program, you must have a prescription from a doctor, and after that fill out a questionnaire and receive a card. The range of products covered by the discount is updated regularly. As an example, below is a list of Pfizer drugs that are subject to discounts in pharmacies of a large Russian network (IFK Pharmacy):
. "Liprimar" - a means that reduces cholesterol in the blood.
. "Kaduet" is a drug intended for the treatment of cardiovascular diseases.
. "Norvask" - a remedy for the treatment of diseases of the heart and blood vessels.
. "Akkupro" - drug preparation used to eliminate arterial hypertension.
. "Akkuzid" - a drug also intended for the treatment of arterial hypertension.
. "Xalatan" is a medicine that an ophthalmologist prescribes for the treatment of glaucoma.
The list also includes Viagra, Dalacin, Inspra, Celebrex, Xalacom. The Caring for You project certainly has some limitations. So, within the framework of the program, you can purchase at a discount no more than two packages of one of the drugs on the list. Pfizer's partners are pharmacy chains with a total of about 9,000 points in more than seventy Russian cities.
American pharmaceutical corporation, which is a leader in the production of medicines for the treatment and prevention of various diseases in all areas of medicine, the company is also engaged in the development and improvement of biotechnologies in the field of pharmaceuticals to fight HIV, for this huge amounts of money are invested in experiments and the production of drugs
Pfizer definition, Pfizer history, Pfizer name etymology, Pfizer management, Pfizer activities, Pfizer products, Pfizer in the Russian Federation, Pfizer financials, Pfizer shares, Pfizer scandals
Pfizer is, definition
Pfizer what is it American pharmaceutical company, one of the largest in the world. The company produces the world's most popular drug, Liprimar (atorvastatin, used to lower blood cholesterol levels).
Pfizer, what is it - is it global biopharmaceutical company. Inventor and manufacturer of the world-famous drug Viagra.
Pfizer where it is the largest pharmaceutical company, the leader of the world pharmaceutical market, today Pfizer owns a leading portfolio of innovative drugs for the treatment and prevention of various diseases. Pfizer is a leader in the development of new drugs for the treatment of diabetes, cancer and cardiovascular diseases.
Pfizer where is The company, which was founded in 1849 in Brooklyn, is now also headquartered in New York. Starting from a modest production of fine chemicals, Pfizer has grown into the largest pharmaceutical company, the leader of the global pharmaceutical market.
Pfizer is the largest American pharmaceutical corporation, whose name was given by the name of one of the founders, a German by birth, Charles Pfizer (Charles Pfizer).
Pfizer is American corporation, which is the largest developer and manufacturer of pharmaceutical products in the world and the undisputed leader of the industry.
Pfizer is an American company that started as a modest fine chemicals business and grew into one of the largest pharmaceutical companies.
American pharmaceutical corporation Pfizer
Pfizer history
The history of the creation of Pfizer
The company's rapid growth began in 1880 when they produced citric acid. The company continued to buy property to expand its laboratory and factory, in a block bounded by the streets of Baltlet Street, Harrison Avenue, Gerry Street, and Flushing Avenue. These rooms are still used as ancillary workshops. Pfizer established its administrative headquarters at 81 Maiden Lane in Manhattan.
The beginning of the history of Pfizer (1910)
By 1910 (by which point sales had reached $3 million) Pfizer was in the business of fermentation technology. This knowledge was used to mass-produce penicillin during World War II, at the behest of the US government. This antibiotic was very much needed by the wounded soldiers of the Allied forces, and soon they began to call it "life-giving medicine." Most of the penicillin that the Allied troops received during the Normandy landings was donated by Pfizer.
Pfizer's worldwide distribution network (1950)
By 1950, the company was represented in Belgium, Cuba, Panama, and also in.
Introduction of new technologies by Pfizer (1980-1990)
In the 80s and 90s of the XX century, the company experienced intensive growth, which was associated with the sales of new popular drugs.
Acquisition of Warner-Lambert by Pfizer Corporation (2000)
In 2000, Pfizer merged with Warner-Lambert and acquired all rights to the drug Lipitor (atorvastatin), previously the market for this drug was divided between Warner-Lambert and Pfizer. Warner-Lambert was located in Morris Plains, New Jersey, and this former headquarters has now become a major base for Pfizer's operations.
Established Products - drugs that have lost patent protection;
Purchase of pharmaceutical giant Wyeth by Pfizer (2009)
On January 26, 2009, Pfizer agreed to buy another pharmaceutical giant for $68 billion. The transaction was completed in October 2009. The largest pharmaceutical industries are GlaxoSmithKline PLC and Pfizer Inc. merged their HIV care businesses into a single subsidiary. This is a unique solution, especially for two competing companies. Thus, GlaxoSmithKline and Pfizer hope to breathe new life into a problematic business, according to the Journal.
Purchase of the Wyeth Company
According to experts, the deal demonstrates that pharmaceutical companies are ready to do anything to increase the level of sales when their most promising products suddenly lose popularity. Glaxo will own 85% of the new corporation, while Pfizer will own 15% of the firm. the new WallStreet is valued at $5 billion (7.5 billion) and has held 19% of the HIV drug market since then.
The British organization GlaxoSmithKline is one of the largest manufacturers of antiretroviral drugs for the treatment of HIV infection in the world. However, it sells those drugs that were developed relatively long ago, and this direction of the organization is not developing as fast as we would like. Glaxo has relatively few new developments in HIV treatment.
The American firm Pfizer has the opposite situation. It manufactures relatively few drugs for HIV, but it has several new drugs for the virus in various stages of development. Organizations hope that by pooling their resources, they will be able to reduce the price of HIV drugs and expand this business, giving it new potential for . The merger reflects a general trend in the modern pharmaceutical industry, which is trying to cope with two major problems, the decline in patent medicines and the difficulty in developing new drugs.
On Tuesday, Pfizer shares rose 0.43% to over $30 a share. In recent years, the corporation began to explore new markets, first of all, I offer the well-known drugs Liviton and Viagra. So we can conclude that Pfizer's growth will continue in the near future.
In 2012, the company's sales fell by 8% to $57.9 billion, which was associated with the emergence of generics for a number of its drugs, including the cholesterol-lowering drug Lipitor. It is one of the best selling drugs in the US and the world. In 2012, sales of Lipitor to Pfizer fell by 60%. Revenue from the sale of Viagra (6th place among the company's best-selling drugs) increased by 4% to $2.1 billion.
The struggle of the finances of large pharmaceutical companies
Pfizer Profit Report
In terms of one share for the half year, it was $0.8 compared to $0.81 per share a year earlier. Pfizer's revenue for the reporting period decreased by 6%, amounting to $22.72 billion, follows from the American corporation.
Net profit of the pharmaceutical company Pfizer Inc. according to the results of the first half of this year, it decreased by 5% compared to the same period in 2014 and reached $5.002 billion, follows from the financial statements of the American corporation.
Net income per share for the half year was $0.8 compared to $0.81 per share a year earlier. Pfizer's revenue for the reporting period decreased by 6%, amounting to $22.72 billion. According to the results of the second quarter, the net profit of the pharmaceutical giant decreased by 10% - to 2.63 billion dollars, in terms of one share amounted to 0.42 dollars (0.45 dollars a year ago). Pfizer quarterly revenue was $11.85 billion (down 7%).
The company notes that second-quarter results reflect continued business development and new product launches in the US market. Pfizer expects 2015 revenue to be between $45 billion and $46 billion, up from $44 billion to $46 billion.
Revenues from sales of modified Pfizer drugs
The official press release states that since the proceeds from the sale of 11 existing drugs were $1.6 billion in 2008, the new firm would have enough financial stability to invest in new developments.
Among the new drugs of the organization, an experimental integrase inhibitor, which is currently undergoing the second stage of clinical trials, two new non-nucleoside reverse transcriptase inhibitors, also in the second stage of clinical trials; two CCR5 antagonists, in Phase I and Phase II clinical trials; and one PK enhancer, a brand new class of drugs currently in phase I clinical trials.
The official press release states that the organization will develop new combinations of existing fixed-dose drugs, as well as develop new drugs. The firm intends to invest in early stages development and discovery of new substances that could become anti-HIV drugs. The new firm will also have exclusive rights to any new HIV drug developed by GlaxoSmithKline or Pfizer.
Such an alliance between the two companies is considered unusual in the industry, as major pharmaceutical firms are tough on each other over drug sales, attracting talent, and bringing new drugs to market. However, this is not the first such case, for example, in 2007, two large organizations entered into a partnership to develop and distribute two diabetes drugs.
One of Pfizer's financial proposals
Pfizer shares
Shares of the North American corporation increased in price by 0.55% and reached 33.17 dollars. USA. The market capitalization of Pfizer at the beginning of February this year amounted to a whopping $209.63 billion. USA. I can recommend keeping in Pfizer, there is every reason to believe that the corporation's assets will grow in the near future. Pfizer shares are included in the industrial calculation base April 8, 2004
Pfizer scandals
The events that happened to Pfizer and caused a conflict with one or another side of the activity.
Child poisoning criminal case in Nigeria against Pfizer (1996)
In 1996, as a result of an illegal trial of the drug Trovan in Nigeria (Kano), 11 children died, several dozen became disabled. A criminal case was initiated against Pfizer, which ended in a settlement agreement. Subsequently, 546 people filed claims against the company. As a result, the experts established the company's guilt in the death of four children (compensations of $175,000 were paid to their families).
Pfizer fined a record $2.3 billion (2009)
In September 2009, Pfizer was fined a record $2.3 billion among US pharmaceutical companies in the United States for improperly advertising four drugs, the pain reliever Bextra, the atypical antipsychotic Geodon (in Russia it is sold under the name Zeldox (Ziprasidone), the antiepileptic drug Lyrica, and antibiotic Zyvox.
Charge of bribery of subsidiaries of Pfizer (2012)
In August 2012 in the US, Pfizer was sentenced to $60 million after accusing the company of bribery. It turned out that two Pfizer subsidiaries spent more than $2 million between 1997 and 2006 on bribes reported as . In addition, employees of enterprises that bought Pfizer drugs could count on a “premium” of 5% of the transaction amount. Subsidiaries tried to hide these frauds from the parent company. In its official statement, Pfizer argued that if management had known about the methods of the "daughters", they would never have approved them.
Pfizer management
Management personnel and owners of Pfizer. Pfizer management pays great attention and allocates funding to research and development in the field of new drugs. The most successful Pfizer drugs were Diflucan - an antifungal drug, Viagra - a drug for the treatment of erectile dysfunction, Geodon - a drug for the treatment of schizophrenia, Vfend - a drug for the treatment of fungal infections, Replax - for the treatment of migraine, Caduet - a drug that lowers cholesterol and high blood pressure, and many others. other drugs for the treatment of diabetes, cancer, cardiovascular diseases.
The priority direction for today is the development of drugs for AIDS and infectious diseases. The constant introduction of new technologies and progressive developments have allowed Pfizer to constantly develop and reach new levels, today it is the world leader in pharmacology, the company's shares were included in the Dow Jones calculation, which indicates the influence and success of the company.
General manager of the entire management team.
The organization's current board of directors is as follows - Michael S. Brown, M. Anthony Burns, Robert Barth, Don Cornwell, William H. Gray, Constance Corner, William Howell, Stanley Ikenberry, Jeff Kindler (Chairman), George Lorch, Dana Mead , Ruth J. Simmons, William Steer.
Pfizer General Counsel Jeff Kindler
Chairman of the Board of Pfizer.
Pfizer's activities in the global market
Pfizer is the inventor and manufacturer of the world famous drug Viagra. The production of drugs is carried out at the company's factories located in the USA, Great Britain, Germany, Turkey (46 in the world in total). There are representative offices in more than 100 countries of the world, including Russia. The main divisions of the company: Human Health, Animal Health and Corporate Groups.
Today we own a leading portfolio of innovative drugs for the treatment and prevention of various diseases. Pfizer is a leader in the development of new drugs for the treatment of diabetes, cancer and cardiovascular disease. The organization annually invests about 7.5 billion dollars in scientific research aimed at creating new effective drugs. The organization operates in more than 150 countries around the world. Research centers are located in England (Sandwich) and the USA (Groton and New England, La Jolla, St. Louis, Rinat, (Massachusetts)).
In order to successfully meet the needs of patients and clients of the company, as well as meet our obligations to shareholders, we constantly improve business methods, monitor the transparency of the organization's activities and always take into account the opinions of healthcare professionals in making management decisions. We firmly believe that it is possible to ensure guaranteed access of the population to the latest medicines and quality medicine only through joint work with all parts of the healthcare system - from patients to doctors, from local healthcare institutions to international governmental and non-governmental organizations.
The firm's rapid growth began in 1880 when they began producing citric acid. The organization continued to buy property to expand its laboratory and factory in the neighborhood bounded by the streets of Balllet Street, Harrison Avenue, Gerry Street and Flushing Avenue. These rooms are still used as ancillary workshops. Pfizer established its administrative headquarters at 81 Maiden Lane in Manhattan.
Pfizer's sphere of influence
Thanks to the continuous progress in the field of medicine and pharmacy, more people in the world are getting the opportunity to fight serious diseases, prolonging life and improving health. At the same time, the demand for new drugs continues to rise steadily.
Pfizer - life lessons
Every year, Pfizer provides high-quality, effective and reliable pharmaceutical products to more than 150 million people. By dedicating tremendous efforts to the development of innovative medicines, Pfizer creates unique products, many of which become significant medical discoveries. Some of the organization's innovative drugs are the only approved drugs for certain serious diseases.
Pfizer and the firm's partners conduct research and development of new drugs in 10 therapeutic areas:
Allergology and respiratory diseases;
Cardiovascular, metabolic and endocrine diseases;
Gastrointestinal and hepatological disorders;
urinary disorders;
Infectious diseases;
inflammation;
Neurology;
Oncology;
Ophthalmology;
In partnership with other companies and government and non-government organizations, Pfizer strives to maximize the availability of medicines to patients and increase their awareness.
Pfizer also cares about animal health. Our Animal Health division is a global leader in veterinary products, bringing new products to the market every year for the treatment and prevention of diseases in both farm and pet animals.
Pfizer actively collaborates with doctors working in various fields of medicine, providing them with the resources they need to improve the quality of medical services. We provide detailed information about Pfizer prescription drugs, as well as participation in patient support and research
Various Pfizer co-production arrangements
Pfizer Inc. announced the conclusion with the Indian generic organization "Aurobindo Pharma Ltd" on the production and the latest drugs of competitors that have lost patent exclusivity, reports "The International Herald Tribune". David Simmons, head of Pfizer's established products unit, said his firm is committed to effectively reshaping established products.
D. Simmons also said that Pfizer is going to expand its product portfolio through additional interaction with Aurobindo and other companies. In addition, according to D. Simmons, Pfizer is considering marketing strategies for generic drugs in emerging markets.
Under the terms, Aurobindo will manufacture and market generic drugs, of which 39 are destined for the US market, 20 for European countries, and an additional 11 for France. In addition, Pfizer will acquire market analysis rights for 12 injectable antibiotics in the US and Europe, including penicillins and cephalosporins. Exactly which drugs will be licensed is not known, but it is known that they will cover a wide range of pharmacotherapeutic classes, including drugs for the treatment of cardiovascular diseases and diseases of the nervous system. According to Pfizer, annual generic drugs by 2013 will amount to more than $200 million. USA. Financial details of the agreement were not disclosed.
Le Funtleyder from Miller Tabak & Co. noted that this is a good undertaking, which fits well into the recently announced Pfizer strategy. In addition, it is important for organizations to support their unit, since generic drugs will play a large role in health care reform in the future.
Achievements to improve the production of Pfizer drugs
We list such achievements:
Successful implementation in clinical practice USA of the newest and most promising drug for the treatment of degenerative diseases of the retina Macugen (pegaptanib sodium), which effectively eliminates a number of major etiopathogenetic factors of blindness (developed jointly with the research company Eyetech Pharmaceuticals, Inc.);
Market launch of the antimycotic Vfend (voriconazole) for systemic use;
FDA approval of new drug registration documentation for Exubera (inhaled insulin), a potentially important and promising drug for the treatment of patients with both types of diabetes mellitus (developed jointly with sanofi-aventis and Nektar Therapeutics);
Significant progress in the creation of a whole stream of products to replenish the portfolio of Pfizer Corporation, the line of research and development of drugs has 149 new molecules, 78 projects are being carried out in the field of improving existing drugs;
The success of streamlining our Human Health business to better respond to market needs, operate more efficiently and productively will, among other things, enable the corporation to achieve its $4 billion target of 2008 cost savings. US on an annualized basis;
A choice of new business approaches to address the most pressing issues facing healthcare systems in the US and around the world.
Pfizer development plans
According to Jeff Kindler, Pfizer no longer intends to depend on the success of a few blockbusters. This is the main reason for the acquisition of the Wyeth Company, one of the first large companies to invest in biotechnology.
Pfizer will focus on biopharmaceuticals - vaccines and treatments for Alzheimer's disease and cancer, instead of favoring conventional drugs such as hypocholesterolemic and antihypertensive drugs (Lipitor, US sales - 13% of the company's total (more than $ 6 billion) funds , as well as antidepressants.The company also intends to actively work in the markets for drugs for older people.
Pfizer Working Conditions
Description of the process of training personnel, hiring and doing business in the company.
Recruitment for Pfizer
In connection with the constant development of the company, recruitment is carried out throughout the year as vacancies become available. The main requirement for candidates for positions related to the promotion of drugs is a higher medical education, while work experience in other companies is optional. For other areas of work, experience in relevant areas is desirable.
Pfizer - 20 years in Russia
Often, when opening vacancies, the company tries to close them at the expense of internal reserves, providing its employees with the opportunity for professional and career growth. Preference is given to well-educated, energetic candidates who are interested in hard work, professional growth and success.
Staff training at Pfizer
The company has its own department of vocational training, which allows for intensive training of employees both at the initial stage and in the course of further work. Since the programs are developed not only taking into account the peculiarities of the Russian market, but also based on global criteria for professionalism, Russian employees acquire an international level of skills and knowledge. Corporate international trainings and seminars are held. Training programs take into account the results of regular employee performance appraisals.
Pfizer social package
The company offers all its employees a health and life insurance program, as well as social benefits provided for by labor. Paid expenses for the use of a worker, mobile. There is a premium plan based on performance.
To date, more than 100 Pfizer products have been registered in Russia. These are drugs for the treatment of diseases of the cardiovascular system, the musculoskeletal system, rheumatoid arthritis, urological drugs, medicines for neurology and endocrinology, antibiotics, a wide range of oncological and hematological drugs, vaccines, including pneumococcal vaccine, and vitamins.
Pfizer in the pharmaceutical market of the Russian Federation
Development of the structure of Pfizer in Russia
The history of Pfizer in Russia began in 1992. Then, in the early 90s, the top management of the company, in an effort to make its products available to a larger number, registered the first Russian representative office. Its main task was marketing support and promotion of drugs manufactured by the company.
In 1995, the first representative office of Pfizer's veterinary division, Pfizer Animal Health, appeared in the Russian Federation. Possessing considerable potential, the Russian market demanded a certain flexibility from Pfizer, however, such basic moral and ethical principles as fidelity to quality and care for patients remained unchanged.
In 2000, after another summing up of the company's work, it was decided to increase the number of medical representatives in the Russian Federation. This contributed to the further growth of the company's performance indicators. In 2003, another significant event in the history of Pfizer took place - after the merger with the pharmaceutical company Pharmacia, Pfizer had the opportunity to expand the portfolio of hospital drugs promoted to the Russian market. By 2007, the company's representatives worked in more than 50 cities of the Russian Federation, from Kaliningrad to Vladivostok.
State of the Russian pharmaceutical market
Access to Pfizer products for Russian consumers
Thanks to the activities of Pfizer, not only well-known drugs, but also the latest scientific developments have become available to Russian consumers. To date, more than 100 Pfizer products have been registered in Russia. 14 of them are world leaders in their therapeutic groups. These are drugs for the treatment of diseases of the cardiovascular system, the musculoskeletal system, urological drugs, medicines for neurology and endocrinology, antibiotics, a wide range of oncological and hematological drugs.
As a socially driven company, Pfizer is committed to maximizing the availability of its products to all segments of the population, regardless of income level. To this end, the company actively participates in the provision of preferential drug coverage, cooperates with the Russian Academy of Medical Sciences, implementing joint projects.
The high qualification of Pfizer employees, a well-thought-out management style, an effective marketing strategy, loyalty to the traditions of quality, adherence to ethical business principles - all this allows Pfizer to be one of the leaders of the Russian pharmaceutical market for 18 years. The head of the Pfizer representative office in Russia is Danil Blinov (2011). In 2008, Pfizer LLC was established and the first warehouse of the company's products was opened in Russia (12 km from the Moscow Ring Road). There is no own production in the Russian Federation.
Pfizer products
The company's diversified product portfolio includes biologics, small molecule drugs and vaccines for humans and animals, as well as health food products and a range of well-known OTC products worldwide. The organization produces drugs for a wide range of consumers under the well-known brands Benadryl, Sudafed, Listerine, Desitin, Visine, Ben Gay, Lubriderm, Zantac75 and Cortizone. Pfizer is the inventor and manufacturer of the world famous drug Viagra.
Production of preparations is carried out at the factories of the company located in the USA, England, France, Italy, Holland, Germany, Turkey (in total - in 46 countries of the world). There are representative offices in more than 100 countries of the world, including the Russian Federation.
Pfizer Antibacterials
Antibacterial drugs are used in the treatment of various infectious diseases.
Zyvox Pfizer antimicrobial agent
Synthetic antibacterial drug, belongs to a new class of antimicrobial agents, oxazolidinones, active in vitro against aerobic gram-positive bacteria, some gram-negative bacteria and anaerobic microorganisms. Linezolid selectively inhibits protein synthesis in bacteria. By binding to bacterial ribosomes, it prevents the formation of a functional 70S initiation complex, which is an important component of the translation process in protein synthesis.
Tazocin Pfizer broad spectrum antibiotic
Piperacillin monohydrate (piperacillin) is a semi-synthetic broad-spectrum bactericidal antibiotic with activity against many Gram-positive and Gram-negative aerobic and anaerobic bacteria. Thus, Tazocin combines the properties of a broad-spectrum antibiotic and a beta-lactamase inhibitor.
Tygacil Pfizer antibiotic
The antibiotic tigecycline belongs to the class of glycylcyclines, structurally similar to tetracyclines. Inhibits protein translation in bacteria by binding to the 30S-subunit of the ribosome and blocking the penetration of aminoacyl-tRNA molecules to the A-site of the ribosome, which prevents the inclusion of amino acid residues in growing peptide chains. Tigecycline is believed to have bacteriostatic properties.
Pfizer Vaccines
A vaccine is a medical or veterinary drug designed to create immunity to infectious diseases. The vaccine is made from weakened or killed microorganisms, their metabolic products, or from their antigens obtained by genetic engineering or chemical means.
Prevenar Pfizer for the prevention of pneumococcal infections
Vaccine to prevent pneumococcal infections.
Pfizer drugs used in gynecology
The stimulator of heart activity is a synthetic analogue of prostaglandin E2. Glucocorticosteroids are prescribed only for hormonal disorders. As anti-inflammatory drugs, they are not used in gynecology. For the treatment of female diseases, drugs of the second and third groups are used. Medicines are prescribed for colpitis of various origins, vaginal dysbacteriosis, inflammatory processes in the uterus, appendages, fallopian tubes.
Prepidil Pfizer for use in childbirth
Helps in the process of stimulating the maturation of the cervix in the presence of medical and obstetric indications for the induction of labor at full-term and close to full-term pregnancy.
Pfizer drugs used in gastroenterology
The indication for their appointment to patients with diseases of the gastrointestinal tract is the syndrome of maldigestion and malabsorption of various origins with or without exocrine pancreatic insufficiency.
Sub Simplex Pfizer for bowel treatment in children
By reducing the surface tension at the phase interface, it hinders the formation and contributes to the destruction of gas bubbles in the intestinal contents. The gases released during this can be absorbed by the intestinal walls or excreted due to peristalsis. Prevents interference and overlapping of images during sonography and radiography; promotes better irrigation of the mucous membrane of the colon with a contrast agent, preventing the contrast film from breaking. Simethicone changes the surface tension of gas bubbles formed in the contents of the stomach and intestinal mucus, and causes their destruction. The released gases are absorbed by the intestinal wall or removed during intestinal peristalsis. Simethicone removes foam in a physical way, does not enter into chemical reactions.
Preparation Sub simplex Pfizer
Pfizer drugs used in cardiology
With high blood pressure, the heart works with overload, the mass of the heart muscle increases, and hypertrophy of the left ventricle of the heart develops. Also, the vessels of the heart, brain, kidneys, and retina of the eyes work with overload. Over time, patients with high blood pressure develop cardiovascular complications: myocardial infarction, stroke, hemorrhages in the fundus. Currently, very effective and safe drugs have been created that reduce blood pressure, which not only reduce blood pressure to the required levels, but also prevent the development of cardiovascular complications. The drugs are selected by the attending physician. The course of treatment is lifelong.
Akkuzid Pfizer cardiac drug
Combined antihypertensive agent (diuretic + angiotensin-converting enzyme inhibitor).
Accupro Pfizer to improve blood circulation
Quinapril increases exercise tolerance. With prolonged use, it contributes to the regression of myocardial hypertrophy in patients with arterial hypertension, improves blood supply to the ischemic myocardium. Enhances coronary and renal blood flow. Reduces platelet aggregation.
Inspra Pfizer treatment for heart disease
Eplerenone causes a persistent increase in the concentration of renin in the blood plasma and aldosterone in the blood serum. Subsequently, renin secretion is suppressed by aldosterone by a feedback mechanism. At the same time, an increase in renin activity or the concentration of circulating aldosterone does not affect the effects of eplerenone.
Caduet Pfizer for the treatment of combined cardiovascular diseases
KADUET® is combination drug, intended for the treatment of combined cardiovascular diseases (arterial hypertension / angina pectoris and dyslipidemia).
Liprimar Pfizer hypolipidemic agent
Atorvastatin is a selective competitive inhibitor of HMG-CoA reductase, a key enzyme that converts 3-hydroxy-3-methylglutaryl-CoA to mevalonate, a precursor of steroids, including cholesterol, a synthetic lipid-lowering agent.
Norvasc Pfizer for cardiovascular disorders
In patients with cardiovascular diseases (including coronary atherosclerosis with lesions of one vessel and up to stenosis of 3 or more arteries and atherosclerosis of the carotid arteries), who have had a myocardial infarction, percutaneous transluminal angioplasty of the coronary arteries (TLP) or suffering from angina pectoris, the use of Norvasc prevents the development of thickening of the intima-media of the carotid arteries, significantly reduces mortality from cardiovascular causes, myocardial infarction, stroke, TLP, coronary artery bypass grafting, reduces the number of hospitalizations for unstable angina and progression of chronic heart failure (CHF), reduces the frequency of interventions, aimed at restoring coronary blood flow.
RevatioPfizer for lowering blood pressure
Tablets, coated film sheath, white or off-white, round, biconvex, engraved with "RVT 20" on one side and "Pfizer" on the other side.
Pfizer drugs used in lincosamide
Lincosamides are a group of antibiotics that includes natural antibiotic lincomycin and its semi-synthetic analogue clindamycin. They have bacteriostatic or bactericidal properties, depending on the concentration in the body and the sensitivity of microorganisms.
Champix Pfizer for the treatment of smoking addiction
Patients who are unwilling or unable to set a goal to quit smoking within 1-2 weeks may be offered to start treatment, with the option of choosing their own quit date within 5 weeks. Patients who had previously attempted to quit smoking with varenicline and who were retreated with varenicline had a better rate of confirmed sustained abstinence compared with placebo.
Champix Pfizer
Pfizer drugs used in ophthalmology
Ophthalmology is a field of medicine that studies the eye, its anatomy, physiology and disease, as well as developing methods for the treatment and prevention of eye diseases.
Xalacom Pfizer for the treatment of intraocular pressure
The mechanism for reducing elevated intraocular pressure (IOP) in these components is different, which provides an additional reduction in IOP compared to the effect achieved when using each of these components in the form of monotherapy.
Xalatan Pfizer for the prevention of intraocular pressure
Reduces elevated intraocular pressure (IOP) in adults and children (over the age of 1 year) with open-angle glaucoma or increased ophthalmotonus.
Pfizer drugs used in oncology
Cancer is a broad and heterogeneous class of diseases. Oncological diseases are systemic and affect, one way or another, all human organs and systems. There are many forms and options for cancer treatment. Although patients often perceive a cancer diagnosis as a verdict, not all of them even malignant tumors lead to death. Modern studies have shown that cancer cells and microtumors regularly appear in every person in the body, which die and resolve under the influence of the antitumor immunity system.
Psychoneurology, a complex of sciences about human behavior. In the understanding of some authors, this concept includes the anatomy and physiology of the nervous system, neuropathology, psychiatry and psychohygiene, psychology, psychotechnics, pedology, a complex of sciences about human behavior. In the understanding of some authors, this concept includes the anatomy and physiology of the nervous system, neuropathology, psychiatry and psychohygiene, psychology, psychotechnics, pedology, a complex of sciences about human behavior. In the understanding of some authors, this concept includes the anatomy and physiology of the nervous system, neuropathology, psychiatry and psychohygiene, psychology, psychotechnics, and pedology.
Zeldox Pfizer antipsychotic drug for the treatment of schizophrenia
Pharmacotherapeutic group, antipsychotic agent (neuroleptic). Treatment of schizophrenia. The drug is effective in the treatment of productive and negative symptoms, as well as affective disorders.
Zoloft Pfizer antidepressant
Antidepressant, a potent specific serotonin (5-HT) reuptake inhibitor in neurons. It has very little effect on the reuptake of norepinephrine and dopamine. At therapeutic doses, sertraline blocks the uptake of serotonin in human platelets. It has no stimulant, sedative or anticholinergic effect.
Lyrics Pfizer for the treatment of patients with epilepsy
The active substance is pregabalin, an analogue of gamma-aminobutyric acid ((S)-3-(aminomethyl)-5-methylhexanoic acid). The pharmacokinetic parameters of pregabalin at steady state in healthy volunteers, in patients with epilepsy who received antiepileptic therapy, and in patients who received it for chronic pain syndromes, were similar.
Lyrica Pfizer
Relpax Pfizer anti-migraine agent
The anti-migraine drug Eletriptan is a member of a group of selective agonists of serotonin vascular 5-HT1B and neuronal 5-HT1D receptors. Eletriptan also has a high affinity for serotonin 5-HT1F receptors and has a moderate effect on 5-HT1A, 5-HT2B, 5-HT1E and 5-HT7 serotonin receptors.
Sermion Pfizer to improve blood circulation in the brain
An ergoline derivative that improves metabolic and hemodynamic processes in the brain, reduces platelet aggregation and improves blood hemorheological parameters, increases blood flow velocity in the upper and lower limbs. Nicergoline exhibits an α1-adrenergic blocking effect, leading to an improvement in blood flow and has a direct effect on the cerebral neurotransmitter systems - noradrenergic, dopaminergic and acetylcholinergic.
Antifungals are drugs used to treat infections such as athlete's foot, ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis, and others. These drugs are usually available by prescription or over the counter.
Vfend Pfizer broad-spectrum antifungal drug
A broad-spectrum antifungal drug from the triazole group. The mechanism of action of voriconazole is associated with inhibition of 14α-sterol demethylation mediated by fungal cytochrome P450, a key step in the biosynthesis of ergosterol.
Diflucan Pfizer antifungal agent
Fluconazole, a triazole antifungal agent, is a potent selective inhibitor of sterol synthesis in the fungal cell. when taken orally and intravenous administration fluconazole has been active in various animal models of fungal infections.
Diflucan Pfizer
Rheumatology is a specialization of internal medicine dealing with the diagnosis and treatment of rheumatic diseases. The term "rheumatology" itself comes from the Greek word "ρεύμα", meaning "stream, river" and the suffix "-logos", meaning "study". The subject of study of rheumatology are inflammatory and degenerative-dystrophic diseases of the joints and systemic diseases. connective tissue(obsolete name - collagenoses).
Celebrex Pfizer anti-inflammatory drug
Non-steroidal anti-inflammatory drug (NSAID). Celecoxib has anti-inflammatory, analgesic and antipyretic effects by blocking the formation of inflammatory prostaglandins (Pg) mainly through inhibition of cyclooxygenase-2 (COX-2). The induction of COX-2 occurs in response to inflammation and leads to the synthesis and accumulation of prostaglandins, especially prostaglandin E2, while there is an increase in the manifestations of inflammation (swelling and pain).
Enbrel Pfizer for Arthritis
Tumor necrosis factor (TNF-α, TNF) is the main cytokine that supports the inflammatory process in rheumatoid arthritis. An increase in the level of TNF was also found in synovial membranes and psoriatic plaques in patients with psoriatic arthritis, as well as in the plasma and synovial tissues of patients with ankylosing spondylitis.
The field of surgery and cardiology, eliminating the pathology of the cardiovascular system. In particular, cardiac surgery is the most effective way IHD treatment to prevent the development of myocardial infarction.
Fragmin Pfizer anticoagulant
Direct acting anticoagulant. Dalteparin sodium is a low molecular weight heparin isolated by controlled depolymerization (with nitrous acid) of sodium heparin from the mucosa small intestine pigs and subjected to additional purification using ion-exchange chromatography.
Transplantology is a branch of medicine that studies the problems of organ transplantation (in particular, kidneys, liver, heart), as well as the prospects for creating artificial organs.
Rapamun Pfizer strong analgesic
Sirolimus inhibits T-lymphocyte activation by blocking calcium-mediated and calcium-independent intracellular signal transduction. Research data suggest that the mechanism of action of sirolimus differs from that of ciclosporin, tacrolimus, and other immunosuppressants. According to experimental data, sirolimus binds to a specific cytosolic protein - immunophilin.
Urology - area clinical medicine studying the etiology, pathogenesis, diagnosis of diseases of the urinary system, male reproductive system, diseases of the adrenal glands and other pathological processes in the retroperitoneal space and developing methods for their treatment and prevention.
Viagra Pfizer for sexual stimulation
A powerful selective inhibitor of cycloguanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). The implementation of the physiological mechanism of erection is associated with the release of nitric oxide (NO) in the cavernous body during sexual stimulation. This, in turn, leads to an increase in the level of cGMP, subsequent relaxation of the smooth muscle tissue of the cavernous body and an increase in blood flow. Sexual stimulation is a prerequisite for the effectiveness of sildenafil.
Viagra Pfizer
Pfizer Detrusitol for Bladder Treatment
It is a competitive antagonist of cholinergic muscarinic receptors with the highest selectivity for bladder receptors. The 5-hydroxymethyl derivative of tolterodine is also highly specific for muscarinic receptors and does not significantly affect other receptors. Tolterodine reduces the contractile activity of the detrusor, and also reduces salivation. In doses exceeding therapeutic, causes incomplete emptying of the bladder and increases the amount of residual urine.
Cardura Pfizer for the treatment of patients with symptoms of benign prostatic hyperplasia
Appointment of doxazosin to patients with symptoms of benign prostatic hyperplasia (BPH) leads to a significant improvement in urodynamic parameters and a decrease in the manifestations of symptoms of the disease.
Endocrinology - the science of the structure and function of the endocrine glands (endocrine glands), the products they produce (hormones), the ways of their formation and action on the body of animals and humans; as well as about diseases caused by a violation of the function of these glands or the action of these hormones. Endocrinology is one of the youngest and most rapidly developing branches of medicine, dealing with the treatment of diseases associated with disorders in the endocrine system. The problems of endocrinology to some extent affect almost all areas of medicine and are closely related to cardiology, oncology, ophthalmology, gastroenterology, nephrology, neurology, gynecology.
Dostinex Pfizer for the treatment of thyroid disorders
Cabergoline is a dopaminergic derivative of ergoline and is characterized by a pronounced and prolonged prolactin-lowering effect due to direct stimulation of D2-dopamine receptors of lactotropic pituitary cells.
Sources and links
Sources of texts, pictures and videos
wikipedia.org - free encyclopedia collection of terms Wikipedia
academic.ru - information and analytical site about the term
ubr.ua - site of analytics and news about companies and business
Pfizer.com - informational portal about Pfizer
vnutri.org - analytical news site Inside
brandpedia.ru - website of analytics and articles all Available about companies
evolutsia.com - Evolution news and analytics website
cosmomir.ru - information portal Cosmomir
wapedia.mobi - information site for news and articles of Wapedia
apteka.ua - portal of articles All about pharmaceutics
Ua - Any purchase with a discount on the information site
works.tarefer.ru - portal collection of abstracts and reports
grandars.ru - information and analytical portal
catback.ru - information and analytical site about the term
en.academic.ru - site collection of articles and terms
akm.ru - economic news agency on the portal
allendy.ru - economic portal on economics
Bloomberg (Bloomberg) .com - information and analytical agency
catback.ru - scientific articles and educational materials in Economics
Pfizer.com - the official website of Pfizer
finance_investment.academic.ru - financial and investment portal
glav-love.ru - site of news and analytics in business
cosmomir.ru - site of news and articles of various companies
proactions.ru - information and analytical news portal
ambar.ua - portal of products and assortment of companies
medi.ru - site of analytics and information about it
expertoza.com - news and analytics site
pidruchniki.com - portal collection of books and articles
chipsaway.ua - site of news and analytics about economic terms
homearchive.ru - information and analytical portal about business
financial-lawyer.ru - financial and analytical site
5ballov.qip.ru - site for analytics and news about business
amerikos.com - American news and analytics website
glamlemon.ru - products and articles on the portal
directory.paininfo.ru - site of pharmaceuticals and analytics about it
Pfizer.ru - official website of Pfizer in Russia
Links to Internet services
forexaw.com - information and analytical portal for financial markets
Ru - the largest search engine in the world
video.google.com - search for videos on the Internet through Google
play.google.com - various applications on the Internet
docs.google.com - document storage and exchange service
translate.google.ru - translator from the search engine
Google youtube.com - search for video materials on the largest portal in the world
Ru - the largest search engine in the Russian Federation
wordstat.yandex.ru - a service from Yandex that allows you to analyze search queries
video.yandex.ru - search for videos on the Internet through Yandex
images.yandex.ru - image search through the service
Yandex ru.tradingeconomics.com - service of economic data of the countries of the world
Article Creator
Odnoklassniki.Ru/profile/459752031180 - profile of the author of this article in Odnoklassniki
Plus.Google.Com/u/0/104482530940845863083/posts - profile of the author of the material in Google+
My.Mail.Ru/Mail/miroshnichenko.b.o - profile of the author of this material in My World
-Mergers and Acquisitions - Warner-Lambert / Parke-Davis / Agouron - Owners and Management
Activity
Pfizer in the Russian Federation -Company pfizer(USA) -Reorganization of the organization Development plans -Scandals
Field of activity
Agreements
Pfizer, Inc. - this american pharmaceutical organization, one of the largest in the world. Firm produces the world's most popular drug Lipitor (Atorvastatin, used to lower blood cholesterol levels). Also sells the following popular drugs: Lyrica, Diflucan, Citromax, Viagra, Celebrex. Pfizer shares were included in the Dow Jones Industrial Average on April 8, 2004. The headquarters is located in New York, and the main research center is located in Groton, Connecticut.
History
Pfizer was founded in 1849 in Brooklyn and is now also headquartered in New York. Starting from a modest fine chemicals business, Pfizer has grown into the world's largest pharmaceutical organization and the world's leading pharmaceutical company.
Today we own a leading portfolio of innovative drugs for the treatment and prevention of various diseases. Pfizer is a leader in the development of new drugs for the treatment of diabetes, cancer and cardiovascular diseases. The organization annually invests about 7.5 billion dollars in scientific research aimed at creating new effective drugs. The organization operates in more than 150 countries around the world. Research and development centers are located in England (Sandwich) and USA(Groton and New England, La Jolla, St. Louis, Rinat, (Massachusetts)).
In order to successfully meet the needs of the company's patients and clients, as well as meet our obligations to shareholders, we constantly improve business methods, monitor the transparency of the organization's activities, and always take into account the opinions of healthcare professionals in the process of making managerial decisions. We firmly believe that the only way to ensure guaranteed access of the population to the latest medicines and quality medicine is by working together with all parts of the healthcare system - from patients to doctors, from local healthcare institutions to international governmental and non-governmental organizations.
By 1910 (by which point sales had reached $3 million), Pfizer was considered an expert in fermentation technology. This knowledge was used to mass-produce penicillin during World War II, at the behest of the government. USA. This antibiotic was very much needed by the wounded soldiers of the Allied forces, and soon they began to call it "life-giving medicine." Most of the penicillin that the Allied troops received at the Normandy landings was provided by Pfizer.
By 1950, the organization was represented in Belgium, Brazil, Canada, Cuba, Iran, Mexico, Panama, Puerto Rico, Turkey, and also in Britain.
In the 80s and 90s of the XX century, the company experienced an intensive growth, which was associated with the invention and sales new popular drugs.
In 2005, Pfizer was one of 53 companies that supported the inauguration of George W. Bush with a maximum of $250,000.
Warner-Lambert/Parke-Davis/Agouron mergers and acquisitions
In 2000, Pfizer merged with Warner-Lambert and acquired all rights to Lipitor (atorvastatin), before market of this drug was divided between Warner-Lambert and Pfizer. Warner-Lambert was located in Morris Plains, New Jersey, and this former headquarters has now become a major base of operations for the Pfizer organization. The majority of Pfizer's manufacturing facilities, as well as Consumer Healthcare ($3.87 billion in 2005), were sold to Johnson & Johnson in 2006 for $16.6 billion.
Parke-Davis was taken over by Warner-Lambert in 1970, which in turn was taken over by Pfizer in 2000. The headquarters of Parke-Davis was sold a few years ago. Pfizer sold the huge Parke-Davis research complex to the University of Michigan in 2008 for $108 million.
January 26, 2009 Pfizer agreed to buy another pharmaceutical giant Wyeth for $68 billion. The deal was completed in October 2009.
The largest companies in the pharmaceutical industry are GlaxoSmithKline PLC and Pfizer Inc. merged their HIV care businesses into a single subsidiary. This is a unique solution, especially for two competing companies. Thus, GlaxoSmithKline and Pfizer hope to breathe new life into a problematic segment market, according to the Wall Street Journal. According to experts, deal demonstrates that pharmaceutical organizations are willing to do anything to increase the level of sales when their most promising product suddenly falls out of favor. Glaxo will own 85% of the new corporation, while Pfizer will own 15% of the firm. The cost of the new Wall Street is estimated at 5 billion pounds (7.5 billion dollars), and since then it has owned 19% of the HIV drug market.
The British organization GlaxoSmithKline is one of the largest manufacturers of antiretroviral drugs for the treatment of HIV infection in the world. However, it sells those drugs that were developed relatively long ago, and this area of \u200b\u200bthe organization is not developing as fast as we would like. Glaxo has relatively few new developments in HIV treatment.
The American firm Pfizer has the opposite situation. It makes relatively few HIV drugs, but it has several new drugs for the virus in various stages of development. Organizations hope that by pooling their resources they can reduce prices for HIV drugs and expand this business, giving it new potential for development. The merger reflects a general trend in the modern pharmaceutical industry, which is struggling to cope with two major problems: declining revenues from patented drugs and difficulties in developing new drugs.
In an official press release, Andrew Witty, Chief Executive Officer of Glaxo, said: “Today was the day GlaxoSmithKline took a step forward to renew our commitment to produce more medicines with greater efficacy for people living with HIV/AIDS. At the heart of this dedicated organization is a portfolio of products and new developments that will be put to better use thanks to the new firm's strong implementation base and research capacity. This new firm is better positioned to meet existing challenges and increase access to treatment.”
Jeff Kindler, Chief Executive Officer of Pfizer, said: “With the combination of the complementary strengths and capabilities of Pfizer and GlaxoSmithKline, we will create a new global leader in HIV and reaffirm our commitment to treating this diseases. The organization has a large portfolio of HIV treatment products and is strengthened by Pfizer's HIV innovation resources and GlaxoSmithKline's global drug distribution capabilities, enabling the organization to bring new and improved medicines to patients as quickly and efficiently as possible. efficiency. The new organization has the potential to reach more patients and achieve more in the global field of HIV care than either of our companies individually.”
“I think this is an example of how they are trying to cope with existing problems,” said Andrew Whitty during a press conference. - "You can see a new generation of management that is ready to look for new solutions." Whitty became chief executive officer last year. Geoffrey Kindler became CEO in 2006.
The firm's combined businesses reached $1.6 billion in sales. dollars last year and their profit from operations is 870 million pounds. Analysts usually estimate that the sales of such an organization will increase two to three times, so the new firm is valued at $4-5 billion.
Agenerase (amprenavir), a protease inhibitor.
Combivir (zidovudine and lamivudine), a nucleoside reverse transcriptase inhibitor.
Epivir (lamivudine, 3TC), a nucleoside reverse transcriptase inhibitor.
Epzicom (Kivexa, abacavir and lamivudine), a nucleoside reverse transcriptase inhibitor.
Retrovir (zidovudine, AZT), a nucleoside reverse transcriptase inhibitor.
Levixa (Telzir, fosamprenavir), a protease inhibitor.
Rescriptor (delavurdin), a non-nucleoside reverse transcriptase inhibitor (U.S. market only).
Selzentry (Celzentry, maraviroc), CCR5 antagonist.
Trizivir (abacavir, zidovudine and lamivudine), a nucleoside reverse transcriptase inhibitor.
Viracept (nelfinavir), a protease inhibitor (North American market only).
Ziagen (abacavir), a nucleoside reverse transcriptase inhibitor.
The new firm will also continue to develop and test 6 new drugs. In the official press release it says that since revenues from the sale of 11 existing drugs in 2008 amounted to $ 1.6 billion, the new company will have enough financial stability to invest in new developments.
Among the new drugs of the organization is an experimental integrase inhibitor, which is currently undergoing the second stage of clinical trials; two new non-nucleoside reverse transcriptase inhibitors, also in Phase 2 clinical trials; two CCR5 antagonists, in the first and second stages of clinical trials; and one PK enhancer, a brand new class of drugs currently in phase 1 clinical trials.
In the official press release The organization is said to be developing new fixed-dose combinations of existing drugs, as well as developing new drugs. intends to invest in the early stages of development and discovery of new substances that can become anti-HIV drugs. The new firm will also have exclusive rights to any new HIV drug developed by GlaxoSmithKline or Pfizer.
This alliance of the two companies is considered unusual in the industry, as large pharmaceutical firms compete fiercely with each other to sell drugs, attract talent, and bring new drugs to market. However, this is not the first such case, for example, in 2007, two large organizations entered into a partnership to develop and distribute two diabetes drugs.
home gain from such an alliance - reducing the huge risk associated with the development of new drugs. Clinical trials can cost hundreds of millions of dollars, and many drugs are found to be ineffective or unsafe. HIV is considered a very risky area for investment in new developments. There are already more than 20 good and effective drugs, and coming up with something better than them is not an easy task.
Both firms have previously come under fire from HIV activists for being too high prices on drugs in both the rich and the poor countries. This pressure has forced organizations to cut prices over the past few years, and in the poorest countries world prices have fallen to non-commercial levels.
Recently, the HIV treatment business has begun to decline in overall GlaxoSmithKline sales growth. Sales of HIV medicines were up 5% compared to 2007, while the firm's total sales were up 7%. So it needs Pfizer's new developments to "stay in the game," as Whitty says.
Dominique Limet, who has worked for GlaxoSmithKline for many years, will be the CEO of the new organization. French physician, Dr. Limet headed work personalized drug companies
Owners and management
Chairman of the Board of Directors and CEO— Jeff Kindler.
The organization's current board of directors is as follows: Michael S. Brown, M. Anthony Burns, Robert Barth, Don Cornwell, William H. Gray, Constance Korner, William Howell, Stanley Ickenberry, Jeff Kindler (Chairman), George Lorch, Dana Mead, Ruth J. Simmons, William Steer.
Activity
The organization manufactures drugs for a wide range of consumers under the well-known brands Benadryl, Sudafed, Listerine, Desitin, Visine, Ben Gay, Lubriderm, Zantac75 and Cortizone. Pfizer is the inventor and manufacturer of the world famous drug Viagra.
The production of drugs is carried out at the factories of the company located in the USA, England, France, Italy, Holland, Germany, Turkey(in total - in 46 countries of the world). There are representations in more than 100 countries of the world, including in Russian Federation.
According to the British information and publishing agency URCH Publishing, Pfizer is the leader of the global pharmaceutical market (2007) with a market share of 6.2% (closest competitors: GSK - 5.4%, Roche - 4.3%). The main divisions of the organization: Human Health, Animal Health and Corporate Groups.
The total number of employees (at the end of 2008) is 83 thousand people (106 thousand people in 2005).
Annual sales in 2008 were $48.3 billion ($48.4 billion in 2007, $51.3 billion in 2005). The firm's profit is $8.1 billion ($8.14 billion in 2007).
Pfizer's Russian Federation
The head of the representative office of the Pfizer organization in the Russian Federation is Christian Holmer (since October 2009).
In 2008, a legal entity was established. the face of Pfizer LLC and the first warehouse of the company's products was opened in the Russian Federation (12 km from the Moscow Ring Road). There is no own production in the Russian Federation.
Pfizer Company (USA)
In 2000, two companies - leaders in the pharmaceutical business - Pfizer and Warner-Lambert merged to form a new joint organization.
The company's activities are aimed at developing drugs to combat the most severe and common ailments of mankind:
Cardiovascular diseases (Norvask, Accupro, Liprimar),
Impotence (Viagra),
Severe infections (Cefobide and Sulperazon),
Systemic candidiasis (Diflucan),
Prostate adenoma (Kardura)
Depression (Zoloft).
The range of manufactured products is very wide.
The organization's portfolio also includes over-the-counter OTC drugs - the well-known Vizin, Tizin, Ben-Gay, Bonin, Desitin and relatively new production facilities of Parke-Davis (a division of Warner-Lambert): Hexoral, Olint, Sab Simplex
Organization reorganization
At the end of 2008-beginning of 2009, Pfizer underwent a reorganization, new business units were created, more clearly focused on customers:
Pfizer Oncology, engaged in the development and marketing of oncological drugs;
Emerging Markets, uniting the emerging markets of Europe, Latin America, Africa, the Middle East, Asia;
Established Products, responsible for out-of-patent drugs;
Specialty Care, etc.
In November 2008, the Pfizer Regenerative Medicine Research Unit, an independent research unit, was launched to study the nature of stem cells and their potential use in the treatment of degenerative diseases.
Development plans
According to Jeff Kindler, Pfizer no longer intends to depend on the success of a few blockbusters. This is the main reason agreements to acquire a firm that was one of the first large companies to invest in biotechnology.
Pfizer will focus on biopharmaceuticals such as vaccines and treatments for Alzheimer's and cancer, rather than focusing on conventional drugs such as cholesterol-lowering and antihypertensives (Lipitor, US sales: 13% of the organization's total (more than $6 billion) drugs, as well as antidepressants.The organization also intends to actively work in the markets for drugs for older people.
Until 2014, the firm's brands, such as the hypocholesterolemic drug Lipitor, the antihypertensive drug Norvasc, the erectile dysfunction drug Viagra and the glaucoma treatment Xalatan, will lose patent protection. Annual consolidated sales of these medicines is $16.7 billion
Scandals
In 1996, an illegal trial of the antibiotic Trovan in Nigeria ( state Kano) killed 11 children. A criminal case was initiated against Pfizer, which ended with a settlement agreement
Field of activity
Thanks to the continuous progress in the field of medicine and pharmacy, more people in the world are able to fight serious diseases, prolonging life and improving health. At the same time, the demand for new drugs continues to rise steadily.
Every year, Pfizer provides high-quality, effective and reliable pharmaceutical products to more than 150 million people. By dedicating tremendous efforts to the development of innovative medicines, Pfizer creates unique products, many of which become significant medical discoveries. Some of the organization's innovative drugs are the only approved drugs for certain serious diseases.
Pfizer and the firm's partners conduct research and development of new drugs in 10 therapeutic areas:
Allergology and respiratory diseases,
Cardiovascular, metabolic and endocrine diseases,
Gastrointestinal and hepatological disorders,
urinary disorders,
Infectious diseases,
inflammation,
Neurology,
Oncology,
Ophthalmology,
In partnership with other companies and government and non-government organizations, Pfizer strives to maximize the availability of medicines to patients and increase their awareness.
Pfizer also cares about animal health. Our Animal Health division is a global leader in veterinary products, bringing new products to the market each year to treat and prevent diseases in both farm and pet animals.
Pfizer actively collaborates with doctors working in various fields of medicine, providing them with information and resources needed to improve the quality of medical services. We provide detailed information about Pfizer prescription drugs, as well as participation in patient support programs and research
Arrangements
Pfizer Inc. announced an agreement with the Indian generic organization Aurobindo Pharma Ltd to manufacture and license the latter's drugs of competitors that have lost patent exclusivity, The International Herald Tribune reports. David Simmons, head of Pfizer's established products unit, said his firm is committed to effectively reshaping established products.
D. Simmons also said that Pfizer is going to expand its product portfolio through additional interaction with Aurobindo and other companies. In addition, according to D. Simmons, Pfizer is considering marketing strategies for generic drugs in emerging markets.
Under the terms of the concession, Aurobindo will produce and market generic drugs, of which 39 are destined for the US market, 20 for European countries, and an additional 11 for France. In addition, Pfizer will acquire market analysis rights for 12 injectable antibiotics in the US and Europe, including penicillins and cephalosporins. It is not known which drugs will be licensed, but it is known that they will cover a wide range of pharmacotherapeutic classes, including drugs for the treatment of cardiovascular diseases and diseases of the nervous system. Pfizer predicts annual sales of generic drugs by 2013 will be more than $200 million. USA. Financial details of the agreement were not disclosed.
Loading...
